FORT WORTH, Texas, Aug. 6 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., , announced today that it has entered into a confidentiality agreement with a company to register and distribute their advanced wound care collagen products, CellerateRx(R), in Taiwan. “We have had a tremendous response and inquiries from the international community about CellerateRx(R),” states Cathy Bradshaw, President of Wound Care Innovations. “We are very excited about the marketing and distribution of CellerateRx(R) in Taiwan as well as the entire international community.” CellerateRx(R) is FDA cleared for use on acute and chronic wounds which include but are not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and 1st and 2nd degree burns. Its ease of application can increase patient compliance and provide minimal lifestyle interruption.
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For information on the Company please visit our website at www.Celleraterx.com .
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
CONTACT: Cathy Bradshaw, Wound Care Innovations, +1-800-205-7719 ext. 141
Web site: http://www.Celleraterx.com/
